Hand-foot syndrom po podání inhibitorů tyrozinkinázové aktivity

Title in English Hand- Foot Syndrome after Administration of Tyrosinkinase Inhibitors


Year of publication 2010
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Field Oncology and hematology
Keywords targeted therapy; tyrosinkinase inhibitor; sorafenib; sunitinib; skin; toxicity; hand- foot syndrome
Description At present, the dermal toxicity of anti-cancer drugs is ever more apparent in cancer patients. This phenomenon appears, in particular, in relation to the increased administration of targeted anti-cancer treatment, especially of monoclonal antibodies and tyrosinkinase inhibitors (TKI), towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumour cell. Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand- foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib. Developed HFSR may be a strongly perceived adverse eff ect for patients and may lead to dose intensity reduction in the targeted treatment, or to its interruption if necessary. However, a correct approach from the oncologist and dermatologist, including instructions to be provided to the patient on how to prevent a serious grade of HFSR from being developed, may ensure a smooth anti-cancer treatment and a satisfactory quality of life for cancer patients.

You are running an old browser version. We recommend updating your browser to its latest version.

More info